Your browser doesn't support javascript.
loading
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
Jingfan, Zhang; Ling, Li; Cong, Liu; Ping, Li; Yu, Chen.
Affiliation
  • Jingfan, Zhang; China Medical University. Shengjing Hospital. Department of Endocrinology. Shenyang. CN
  • Ling, Li; China Medical University. Shengjing Hospital. Department of Endocrinology. Shenyang. CN
  • Cong, Liu; China Medical University. Shengjing Hospital. Department of Endocrinology. Shenyang. CN
  • Ping, Li; China Medical University. Shengjing Hospital. Department of Endocrinology. Shenyang. CN
  • Yu, Chen; China Medical University. Shengjing Hospital. Department of Endocrinology. Shenyang. CN
Arch. endocrinol. metab. (Online) ; 63(5): 478-486, Sept.-Oct. 2019. tab, graf
Article in English | LILACS | ID: biblio-1038500
Responsible library: BR1.1
ABSTRACT
ABSTRACT Objectives To provide a meta-analysis of the clinical efficacy and safety of sodium glucose co-transporter 2 inhibitors (SGLT2-i), as a combination treatment with metformin in type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control with metformin alone. Materials and methods We have searched randomized controlled trials (RCTs) in the database MEDLINE, Embase and Cochrane Collaborative database. We used mean differences (MD) to assess the efficacy of glycemic and other clinical parameters, and risk ratios (RR) to evaluate the adverse events for safety endpoints. The heterogeneity was evaluated by I2. Results Finally 9 studies were included. SGLT2-i plus metformin had higher reduction level in HbA1C [MD = -0.50, 95% CI (-0.62, -0.38), p < 0.00001], FPG [MD = -1.12, 95%CI (-1.38, -0.87), p < 0.00001], body weight [MD = -1.72, 95% CI (-2.05, -1.39), p < 0.00001], SBP [MD = -4.44, 95% CI (-5.45, -3.43), p < 0.00001] and DBP [MD = -1.74, 95% CI (-2.40, -1.07), p < 0.00001] compared with metformin monotherapy. However, SGLT2-i plus metformin group had higher risk of genital infection [RR = 3.98, 95% CI (2.38, 6.67), p < 0.00001]. No significant difference was found in the risk of hypoglycemia, urinary tract infection or volume related adverse events. Conclusions Although the risk of genital infection may increase, SGLT2-i plus metformin may provide an attractive treatment option to those T2DM patients who are unable to achieve glycemic control with metformin alone, based on its effects on glycemic control, reducing body weight and lowering blood pressure.
Subject(s)


Full text: Available Collection: International databases Health context: Sustainable Health Agenda for the Americas / SDG3 - Health and Well-Being Health problem: Goal 9: Noncommunicable diseases and mental health / Target 3.4: Reduce premature mortality due to noncommunicable diseases Database: LILACS Main subject: Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Metformin Type of study: Controlled clinical trial / Systematic review Limits: Humans Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2019 Document type: Article Affiliation country: China Institution/Affiliation country: China Medical University/CN

Full text: Available Collection: International databases Health context: Sustainable Health Agenda for the Americas / SDG3 - Health and Well-Being Health problem: Goal 9: Noncommunicable diseases and mental health / Target 3.4: Reduce premature mortality due to noncommunicable diseases Database: LILACS Main subject: Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Metformin Type of study: Controlled clinical trial / Systematic review Limits: Humans Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2019 Document type: Article Affiliation country: China Institution/Affiliation country: China Medical University/CN
...